Fig. 2
From: Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis
Schematic depicting of BRAF-monomer with different mutation and their sensitivity to BRAF inhibitors. A Class I mutations result in an active form BRAF monomer, the αC3 is in the OUT position, making it sensitive to αC-out BRAF inhibitors. B The β3-αC3 loop deletion shortens the loop, forced the αC3 in the IN positive, and makes it insensitive to αC-out BRAF inhibitors, but sensitive to αC-in BRAF inhibitors